Work

Supplementary Figure 6 from Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer

Year: 2023

Type: supplementary-materials

Abstract: PDF file - 159K, Erk phosphorylation after treatments with NVP-BKM120 in vivo. Tumor tissues were harvested from MMTV-CreBRCA1f/fp53+/- mice within 3 hours after the last treatment with NVP-BKM120. Tissues were fixed and processed for immunohistochemistry with anti-phospho ERK (Thr202/Tyr204) antibodies. 400 x magnification

DOI: 10.1158/2159-8290.22529211.v1

Authors: Ashish Juvekar, Laura N. Burga, Hai Hu, Elaine P. Lunsford, Yasir H. Ibrahim, Judith Balmañà, Anbazhagan Rajendran, Antonella Papa, Katherine Spencer, Costas A. Lyssiotis, Caterina Nardella, Pier Paolo Pandolfi, José Baselga, Ralph Scully, John M. Asara, Lewis C. Cantley, Gerburg M. Wulf

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362538437

Cites:

Cited by:

Related to: 10